AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.